Dexamethasone Effects in Patients With Refractory Non-Small Cell Lung Cancer Using FLT Positron Emission Tomography
This pilot research trial studies the effects of dexamethasone in patients with non-small cell lung cancer that has not responded after previous treatment. Drugs such as dexamethasone can affect how tumors grow and respond to treatments. Imaging tests, such as fluoro-L-thymidine (FLT) positron emission tomography , use a small amount of radioactive substance to show changes in tumor cells. Studying the effects of dexamethasone on lung tumors using FLT positron emission tomography may help doctors plan better treatments.
Ask AI to explain this studyKey things to know
This describes the study’s primary purpose.
Plus 2 other study approaches.
These are broad labels—not an eligibility decision.
Checked against the public recordLast updated Aug 22, 2025 · Source: ClinicalTrials.gov
Ask the study team to confirm whether enrollment is open.
Interventional
Locations may change over time.
Study sponsor
What this study is about
- Purpose
- Diagnostic
- Study type
- Interventional
- Phase
- Not applicable
- Sponsor
- Barbara Ann Karmanos Cancer Institute
- Interventions being studied
- Drug: Dexamethasone; Device: Device for PET; Other: Laboratory Biomarker Analysis; Procedure: Positron Emission Tomography
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.
- Patients must have histologically or cytologically proven advanced non-squamous NSCLC. Patients may have newly diagnosed recurrent progressive or refractory disease which may be localized or wide spread.
- No chemotherapy for at least 4 weeks and no radiation to the index lesion or clear progression in that lesion (greater than 20% increase in longest diameter).
- Life expectancy of greater than 4 weeks
- Absolute neutrophil count \>= 1,000/mcL (measured within 2 weeks of registration)
- No history of human immunodeficiency virus (HIV) or active infections
- No history of diabetes
- No surgery in the last 2 weeks prior to study enrollment
- Has not received Dex or another corticosteroid in over 4 weeks prior to enrollment
- Ability to understand and the willingness to sign a written informed consent document
- Agreed to FLT-PET imaging and signed consent and eligible FLT-PET protocol 2006-127
- Registered with the clinical trials office of the Karmanos Cancer Center/Wayne State University
Patients must have measureable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as \>= 20 mm with conventional techniques (computed tomography \[CT\], magnetic resonance \[MR\] or PET); lesions in the previously irradiated area can be considered as measureable lesions as long as there has been an increase of at least 10 mm when compared to measurements obtained after completion of radiation
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Wayne State University/Karmanos Cancer InstituteDetroit, Michigan
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Aug 22, 2025. Always confirm current availability with the study team.